Activation of 5-HT3 Receptors Leads to Altered Responses 6 Months After MDMA Treatment

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2010 Jan 7

PMID 20052506

Citations 4

Authors

Norbert Gyongyosi

Brigitta Balogh

Zita Katai

Eszter Molnar

Rudolf Laufer

Kornelia Tekes

Gyorgy Bagdy

Affiliations

Soon will be listed here.

Abstract

The recreational drug "Ecstasy" [3,4-methylenedioxymethamphetamine (MDMA)] has a well-characterised neurotoxic effect on the 5-hydroxytryptamine (5-HT) neurons in animals. Despite intensive studies, the long-term functional consequencies of the 5-HT neurodegeneration remains elusive. The aim of this study was to investigate whether any alteration of 5-hydroxytryptamine-3 (5-HT(3)) receptor functions on the sleep-wake cycle, motor activity, and quantitative EEG could be detected 6 months after a single dose of 15 mg/kg of MDMA. The selective 5-HT(3) receptor agonist m-chlorophenylbiguanide (mCPBG; 1 mg/kg, i.p.) or vehicle was administered to freely moving rats pre-treated with MDMA (15 mg/kg, i.p.) or vehicle 6 months earlier. Polysomnographic and motor activity recordings were performed. Active wake (AW), passive wake (PW), light slow wave sleep (SWS-1), deep slow wave sleep (SWS-2), and paradoxical sleep were classified. In addition, EEG power spectra were calculated for the second hour after mCPBG treatment for each stage. AW increased and SWS-1 decreased in the second hour after mCPBG treatment in control animals. mCPBG caused significant changes in the EEG power in states with cortical activation (AW, PW, paradoxical sleep). In addition, mCPBG had a biphasic effect on hippocampal theta power in AW with a decrease in 7 Hz and a stage-selective increase in the upper range (8-9 Hz). Effects of mCPBG on the time spent in AW and SWS-1 were eliminated or reduced in MDMA-treated animals. In addition, mCPBG did not increase the upper theta power of AW in rats pre-treated with MDMA. These data suggest long-term changes in 5-HT(3) receptor function after MDMA.

Citing Articles

Attenuated Psychotic Symptoms in Adolescents With Chronic Cannabis and MDMA Use.

Wiedmann M, Kuitunen-Paul S, Basedow L, Roessner V, Golub Y Front Psychiatry. 2022; 12:696133.

PMID: 35126190 PMC: 8814345. DOI: 10.3389/fpsyt.2021.696133.

Gene expression analysis indicates reduced memory and cognitive functions in the hippocampus and increase in synaptic reorganization in the frontal cortex 3 weeks after MDMA administration in Dark Agouti rats.

Petschner P, Tamasi V, Adori C, Kirilly E, Ando R, Tothfalusi L BMC Genomics. 2018; 19(1):580.

PMID: 30071829 PMC: 6090855. DOI: 10.1186/s12864-018-4929-x.

Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism.

Leiser S, Iglesias-Bregna D, Westrich L, Pehrson A, Sanchez C J Psychopharmacol. 2015; 29(10):1092-105.

PMID: 26174134 PMC: 4579402. DOI: 10.1177/0269881115592347.

Gene expression analysis indicates CB1 receptor upregulation in the hippocampus and neurotoxic effects in the frontal cortex 3 weeks after single-dose MDMA administration in Dark Agouti rats.

Petschner P, Tamasi V, Adori C, Kirilly E, Ando R, Tothfalusi L BMC Genomics. 2014; 14:930.

PMID: 24378229 PMC: 3902429. DOI: 10.1186/1471-2164-14-930.

References

Rajachandran L, Spear N, Spear L . Effects of the combined administration of the 5-HT3 antagonist MDL 72222 and ethanol on conditioning in the periadolescent and adult rat. Pharmacol Biochem Behav. 1993; 46(3):535-42. DOI: 10.1016/0091-3057(93)90541-z. View

Belforte J, Pazo J . Turning behaviour induced by stimulation of the 5-HT receptors in the subthalamic nucleus. Eur J Neurosci. 2004; 19(2):346-55. DOI: 10.1111/j.0953-816x.2003.03125.x. View

Kilpatrick G, Jones B, Tyers M . The distribution of specific binding of the 5-HT3 receptor ligand [3H]GR65630 in rat brain using quantitative autoradiography. Neurosci Lett. 1988; 94(1-2):156-60. DOI: 10.1016/0304-3940(88)90287-x. View

Fitzgerald J, REID J . Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur J Pharmacol. 1990; 191(2):217-20. DOI: 10.1016/0014-2999(90)94150-v. View

Barnes J, Barnes N, Costall B, Deakin J, Ironside J, Kilpatrick G . Identification and distribution of 5-HT3 recognition sites within the human brainstem. Neurosci Lett. 1990; 111(1-2):80-6. DOI: 10.1016/0304-3940(90)90348-d. View

Rothman R, Baumann M, Dersch C, Romero D, Rice K, Carroll F . Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2000; 39(1):32-41. DOI: 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. View

Adori C, Ando R, Kovacs G, Bagdy G . Damage of serotonergic axons and immunolocalization of Hsp27, Hsp72, and Hsp90 molecular chaperones after a single dose of MDMA administration in Dark Agouti rat: temporal, spatial, and cellular patterns. J Comp Neurol. 2006; 497(2):251-69. DOI: 10.1002/cne.20994. View

Mazzola-Pomietto P, Aulakh C, Murphy D . Temperature, food intake, and locomotor activity effects of a 5-HT3 receptor agonist and two 5-HT3 receptor antagonists in rats. Psychopharmacology (Berl). 1995; 121(4):488-93. DOI: 10.1007/BF02246499. View

Engleman E, Rodd Z, Bell R, Murphy J . The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy. CNS Neurol Disord Drug Targets. 2009; 7(5):454-67. PMC: 2878195. DOI: 10.2174/187152708786927886. View

10.

Pratt G, Bowery N, Kilpatrick G, Leslie R, Barnes N, Naylor R . Consensus meeting agrees distribution of 5-HT3 receptors in mammalian hindbrain. Trends Pharmacol Sci. 1990; 11(4):135-7. DOI: 10.1016/0165-6147(90)90058-g. View

11.

Staubli U, Xu F . Effects of 5-HT3 receptor antagonism on hippocampal theta rhythm, memory, and LTP induction in the freely moving rat. J Neurosci. 1995; 15(3 Pt 2):2445-52. PMC: 6578162. View

12.

Kirilly E, Molnar E, Balogh B, Kantor S, Hansson S, Palkovits M . Decrease in REM latency and changes in sleep quality parallel serotonergic damage and recovery after MDMA: a longitudinal study over 180 days. Int J Neuropsychopharmacol. 2008; 11(6):795-809. DOI: 10.1017/S1461145708008535. View

13.

Balogh B, Molnar E, Jakus R, Quate L, Olverman H, Kelly P . Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA. Psychopharmacology (Berl). 2004; 173(3-4):296-309. DOI: 10.1007/s00213-004-1787-9. View

14.

Yamamoto B, Spanos L . The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol. 1988; 148(2):195-203. DOI: 10.1016/0014-2999(88)90564-x. View

15.

Costall B, Domeney A, Naylor R, Tyers M . Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol. 1987; 92(4):881-94. PMC: 1853731. DOI: 10.1111/j.1476-5381.1987.tb11394.x. View

16.

Schierenbeck T, Riemann D, Berger M, Hornyak M . Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev. 2008; 12(5):381-9. DOI: 10.1016/j.smrv.2007.12.004. View

17.

Bufton K, Steward L, Barber P, Barnes N . Distribution and characterization of the [3H]granisetron-labelled 5-HT3 receptor in the human forebrain. Neuropharmacology. 1993; 32(12):1325-31. DOI: 10.1016/0028-3908(93)90027-z. View

18.

Capela J, Carmo H, Remiao F, Bastos M, Meisel A, Carvalho F . Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol. 2009; 39(3):210-71. DOI: 10.1007/s12035-009-8064-1. View

19.

Parrott A . Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol. 2005; 19(1):71-83. DOI: 10.1177/0269881105048900. View

20.

Shankaran M, Gudelsky G . Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Pharmacol Biochem Behav. 1998; 61(4):361-6. DOI: 10.1016/s0091-3057(98)00103-8. View